June 2, 2017 / 11:26 AM / in 2 months

BRIEF-Bristol-Myers announces first disclosure of data from a cohort of phase 1/2 CheckMate-358 study

1 Min Read

June 2 (Reuters) - Bristol-myers Squibb Co

* Bristol-Myers - Announces first disclosure of data from a cohort of phase 1/2 CheckMate -358 study

* Bristol-Myers Squibb Co says median duration of response has not been reached after 6 months of follow-up

* Bristol-Myers Squibb Co - Grade 3/4 treatment-related adverse events occurred in 12.5% of patients in phase 1/2 checkmate -358 study evaluating Opdivo

* Bristol-Myers - Opdivo showed safety profile consistent with previous results seen with Opdivo monotherapy in other tumor types, in CheckMate -358​ study

* Bristol-Myers - ‍overall response rate of 26.3% in patients with cervical cancer regardless of PD-l1, HPV status and number of prior systemic therapies​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below